GlassScriptPhysician profile
Robin Alyson Mccoy
NPI 1700231503
$2,864.04
in general payments reported to CMS, 2019-2025
36 companies · $574 in 2025
The $574 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $399 · 2023: $851 · 2024: $782 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,940 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.56 |
| Education | $268.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $529.09 | 2021-2025 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $379.45 | 2021-2025 | Erleada |
| Sumitomo Pharma America, INC. | $353.33 | 2023-2025 | Orgovyx, Gemtesa |
| Accord Healthcare, INC. | $177.20 | 2022-2025 | |
| Abbvie INC. | $145.75 | 2022-2025 | |
| Tolmar, INC. | $133.42 | 2023-2025 | Eligard |
| Pfizer INC. | $98.24 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.88 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $86.48 | 2023-2024 | Aveed, Xiaflex |
| 180 Medical, INC. | $56.19 | 2021-2023 | |
| Urogen Pharma, INC. | $55.04 | 2023-2024 | Jelmyto |
| Coloplast Corp | $53.67 | 2023-2025 | Speedicath |
| Procept Biorobotics Corporation | $50.39 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Davol INC. | $48.27 | 2021 | |
| Boston Scientific Corporation | $43.95 | 2022-2025 | Solyx Sis System, Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous) |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $40.93 | 2025 | Bard Urinary Drainage Bag |
| Abc Home Medical Supply, INC. | $38.70 | 2024-2025 | |
| Axonics, INC. | $37.93 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $37.62 | 2024 | Erleada |
| Medtronic, INC. | $36.49 | 2021-2022 | |
| Rochester Medical Corporation | $35.52 | 2022 | |
| Urovant Sciences INC | $32.83 | 2022 | |
| Antares Pharma, INC. | $32.77 | 2023 | Nocdurna, Tlando, Xyosted |
| Convatec INC. | $32.53 | 2025 | |
| Myovant Sciences INC. | $32.09 | 2022 | |
| Endo USA, INC. | $22.96 | 2024 | Xiaflex |
| Adc Therapeutics America, INC. | $22.87 | 2021 | |
| Telix Pharmaceuticals | $22.76 | 2023 | Illuccix |
| Merck Sharp & Dohme LLC | $20.56 | 2024 | Lynparza |
| Sun Pharmaceutical Industries INC. | $20.02 | 2024 | |
| Laborie Medical Technologies Corp. | $19.71 | 2021 | |
| Siemens Medical Solutions USA, INC. | $18.21 | 2024 | Uroskop Omnia Max |
| Hologic Sales and Service, LLC | $18.19 | 2025 | Aptima |
| Novartis Pharmaceuticals Corporation | $16.38 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $14.92 | 2022 | |
| Hollister Incorporated | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.